NCT01238029终止1 期
Combinational Therapy of Capecitabine, Lapatinib and Vinorelbine for the Treatment of Patients With her2/Neu Positive, Relapsed or Metastatic Breast Carcinoma Following Treatment Failure With Trastuzumab
Sponsor GmbH10 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 12
- 试验地点
- 10
- 主要终点
- Identification of maximal tolerable Dose (MTD) of combination with Capecitabine and Lapatinib and Vinorelbine
研究概览
简要总结
The purpose of the study is to investigate safety and efficiency of the triple combination of capecitabine, lapatinib and vinorelbine in patients with metastatic breast cancer.
详细描述
The combination of lapatinib with capecitabine ist a standard therapy für Her2 positive metastatic breast cancer. This study combines this therapy with the additional antimitotic mode of function by vinorelbine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Able to comply with the protocol
- •ECOG performance status 0-1
- •Adequate contraception
- •Confirmed Her2/neu-positive, adenocarcinoma of the breast
- •At least one measurable lesion according to RECIST 1.1 criteria
- •First or second chemotherapy after diagnosis of metastasis
- •Lapatinib treatment indicated (adjuvant trastuzumab treatment <12 months ago or progressive disease with trastuzumab treatment)
- •No signs and symptoms of CHF (chronic heart failure), LVEF (left ventricular ejection fraction) at study start at least 55%
- •Adequate hepatic and renal function value
- •Adequate hematologic function values
排除标准
- •Pregnant or lactating women
- •Concurrent participation in another clinical trial. Prior participation is allowed if the last study medication was administered more than 4 weeks prior to randomization
- •Asymptomatic with regards to tumor illness
- •Previous treatment with lapatinib, capecitabine or vinorelbine
- •Necessity of planned treatment with other chemotherapeutics oder anti-hormone therapy
- •Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of the study
- •Evidence of cardiovascular disease, e.g. myocardial infection, unstable angina pectoris or arrhythmia
- •History of vascular or cardiovascular disease within the past 6 months
- •All illnesses that result in malabsorption of oral medication or inability to take oral medication
- •Concurrent treatment with anti-viral drugs based on sorivudine or with aminoglycosides
- •Concurrent treatment with any drug interfering with study medication, especially, those that induce CYP3A
- •Concurrent treatment with allopurinol
- •Other malignancies (except for basal cell carcinoma of the skin and cervical carcinoma in situ); patient can be included in the study if no recurrent disease has been observed for at least 5 years
- •Concurrent illnesses or other circumstances that could interfere with trial participation, efficacy or safety of the patient
研究组 & 干预措施
Capecitabine, Lapatinib, Vinorelbine
Experimental
干预措施: Lapatinib and Capecitabine and Vinorelbine (Drug)
结局指标
主要结局
Identification of maximal tolerable Dose (MTD) of combination with Capecitabine and Lapatinib and Vinorelbine
时间窗: 4 months
Phase I: Identification of Dosis limiting toxicities and maximal tolerable dose for Combinational therapy (Time Frame: within the first 21 days under medication)
次要结局
- Overall response Rate(12 months)
- Progression free survival(12 months)
- Time to treatment failure (TTF)(12 months)
- Overall survival (OS)(12 months)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast CancerNeoplasms, BreastMetastatic Breast CancerNCT00477464GlaxoSmithKline51
已完成
2 期
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell CarcinomaKidney CancerRenal Cell CarcinomaNCT00496587M.D. Anderson Cancer Center34
已完成
1 期
Phase I Study of Capecitabine in Combination With Cisplatin and IrinotecanSolid TumorsCancerNCT00249977University of New Mexico21
已完成
2 期
Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal CancerColorectal CancerNCT00215982H. Lee Moffitt Cancer Center and Research Institute24
已完成
2 期
Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast CancerBreast NeoplasmNCT00194727University of Washington40